Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Investing.com - Cantor Fitzgerald maintained its Overweight rating on Rezolute (NASDAQ:RZLT) stock on Thursday, though the price target was not specified in the research note. The stock currently trades at $5.91, near its 52-week high of $6.19, after posting impressive returns of 20% year-to-date.
The research firm updated its financial model to incorporate Rezolute’s actual earnings from the second and third quarters of fiscal year 2025, as well as an April capital raise.
These adjustments resulted in a slight decrease to Cantor Fitzgerald’s fiscal year 2025 earnings per share estimates for the company.
The firm also extended its cash flow forecast period for Rezolute, now projecting cash flows through 2039 instead of the previously modeled 2037 timeframe.
"We adjusted our model to reflect FY2Q25A and FY3Q25A actual earnings including an April raise, which slightly decreased our FY2025E EPS estimates. We also forecast cash flows to 2039 instead of 2037. There is no change to our Overweight rating," Cantor Fitzgerald noted in its analysis.
In other recent news, Rezolute, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its drug candidate, ersodetug, for the treatment of hypoglycemia caused by tumor hyperinsulinism (HI). This designation highlights the drug’s potential to significantly improve treatment options for this rare condition. Additionally, Rezolute has completed enrollment for its Phase 3 sunRIZE clinical trial, exceeding its original target with 62 participants, including an estimated 15% from U.S. locations. The company is on track to disclose data from this trial by December 2025.
BTIG analyst Julian Harrison has maintained a Buy rating on Rezolute, with a consistent price target of $15.00, following the trial update. Harrison noted the progress in the sunRIZE trial and the potential of ersodetug, which has also been granted Breakthrough Therapy Designation for congenital hyperinsulinism (cHI). Rezolute plans to file a Biologics License Application (BLA) for ersodetug in cHI around mid-2026, after the anticipated release of top-line data from the sunRIZE study. The company has also posted a patient demographic poster for the sunRIZE study on its website, providing detailed information about the enrolled participants.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.